The DOI matches its Crossref record.
Folate receptor overexpression is associated with poor outcome in breast cancer
Open accessAbstract
The high affinity folate receptor is a membrane‐associated glycoprotein that is preferentially expressed in cancers of epithelial origin and rarely expressed in normal cells. We examined its expression pattern in breast cancer, utilizing a tissue microarray containing samples from 63 invasive breast cancers from women with divergent clinical outcomes. Thirty‐three women comprised the poor outcome group with a median time to recurrence of 1.9 years. Thirty women, the good outcome group, were free of recurrence for a minimum of 7 years after diagnosis. The intensity of folate receptor staining was strongly correlated with outcome. There were two summary categories of staining intensity: weak (n = 42) or strong (n = 21). In the strong staining group, 17 of 21 women (81%) have recurred and their median survival is 2.4 years. In the weak staining group, 16 of 42 women (38%) have recurred. Their median survival is not estimable. After adjustment for tumor size, nodal status, ER status, adjuvant therapy, histology and tumor grade, strong staining for the folate receptor remained significantly associated with poor outcome, p < 0.001. Our work requires validation in a larger cohort, but supports the possibility of using folate receptor‐targeted approaches in the management of breast cancer. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Treating metastatic cancer with nanotechnology
Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3180 · Cited by 1,159
Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics
Hilgenbrink, A. R., & Low, P. S. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20457 · Cited by 625
Self-citationFolate receptor alpha as a tumor target in epithelial ovarian cancer
Kalli, K. R., Oberg, A. L., Keeney, G. L., Christianson, T. J. H., Low, P. S., Knutson, K. L., & Hartmann, L. C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.020 · Cited by 475
Self-citationTargeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advances
Xu, S., Olenyuk, B. Z., Okamoto, C. T., & Hamm-Alvarez, S. F. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.041 · Cited by 467
Targeting folate receptor alpha for cancer treatment
Cheung, A., Bax, H. J., Josephs, D. H., Ilieva, K. M., Pellizzari, G., Opzoomer, J., Bloomfield, J., Fittall, M., Grigoriadis, A., Figini, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9651 · Cited by 430
The folate receptor as a rational therapeutic target for personalized cancer treatment
Assaraf, Y. G., Leamon, C. P., & Reddy, J. A. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.10.002 · Cited by 398
Fundamentals and developments in fluorescence-guided cancer surgery
Mieog, J. S. D., Achterberg, F. B., Zlitni, A., Hutteman, M., Burggraaf, J., Swijnenburg, R.-J., Gioux, S., & Vahrmeijer, A. L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00548-3 · Cited by 389
IR-780 dye loaded tumor targeting theranostic nanoparticles for NIR imaging and photothermal therapy
Yue, C., Liu, P., Zheng, M., Zhao, P., Wang, Y., Ma, Y., & Cai, L. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.05.071 · Cited by 372
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Kon, E., Ad-El, N., Hazan-Halevy, I., Stotsky-Oterin, L., & Peer, D. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00811-9 · Cited by 371
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
Song, D.-G., Ye, Q., Poussin, M., Harms, G. M., Figini, M., & Powell, D. J. (2012) · Blood · doi:10.1182/blood-2011-03-344275 · Cited by 355
Ledermann, J. A., Canevari, S., & Thigpen, T. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv250 · Cited by 347
Molecular imaging for cancer diagnosis and surgery
Hussain, T., & Nguyen, Q. T. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.007 · Cited by 337
Maeng, J. H., Lee, D.-H., Jung, K. H., Bae, Y.-H., Park, I.-S., Jeong, S., Jeon, Y.-S., Shim, C.-K., Kim, W., Kim, J., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.02.068 · Cited by 333
Tumor detection using folate receptor-targeted imaging agents
Sega, E. I., & Low, P. S. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9155-6 · Cited by 291
Self-citationSong, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June, C. H., Coukos, G., & Powell, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0422 · Cited by 287
Phage display screening of therapeutic peptide for cancer targeting and therapy
Saw, P. E., & Song, E.-W. (2019) · Protein & Cell · doi:10.1007/s13238-019-0639-7 · Cited by 279
Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications
Moysan, E., Bastiat, G., & Benoit, J.-P. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300370t · Cited by 225
Shia, J., Klimstra, D. S., Nitzkorski, J. R., Low, P. S., Gonen, M., Landmann, R., Weiser, M. R., Franklin, W. A., Prendergast, F. G., Murphy, L., et al. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.09.013 · Cited by 106
Self-citationAcetylation of MAT IIα represses tumour cell growth and is decreased in human hepatocellular cancer
Yang, H.-B., Xu, Y.-Y., Zhao, X.-N., Zou, S.-W., Zhang, Y., Zhang, M., Li, J.-T., Ren, F., Wang, L.-Y., & Lei, Q.-Y. (2015) · Nature Communications · doi:10.1038/ncomms7973 · Cited by 65
Kefayat, A., Ghahremani, F., Motaghi, H., & Mehrgardi, M. A. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.01.037 · Cited by 54
Amato, R. J., Shetty, A., Lu, Y., Ellis, R., & Low, P. S. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182917f59 · Cited by 42
Self-citation
Metadata
- Authors
- Hartmann, L. C., Keeney, G. L., Lingle, W. L., Christianson, T. J. H., Varghese, B., Hillman, D., Oberg, A. L., & Low, P. S.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2007-05-08
- Volume
- 121
- Issue
- 5
- Pages
- 938-942
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2077250280
- Cited by
- 245
- References
- 0
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.